Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

Aug. 31, 2006

By Aaron Lorenzo

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

Aug. 31, 2006

By Aaron Lorenzo

SGX Stock Plummets After Troxatyl Fails In Phase II/III

Aug. 30, 2006

By Aaron Lorenzo

Shares in SGX Pharmaceuticals Inc. suffered mightily on Tuesday following a Phase II/III study stoppage. (BioWorld Today)

SGX Stock Plummets After Troxatyl Fails In Phase II/III

Aug. 30, 2006

By Aaron Lorenzo

Shares in SGX Pharmaceuticals Inc. suffered mightily on Tuesday following a Phase II/III study stoppage. (BioWorld Today)

EPIX's Contrast Agent Vasovist Dealt Another Setback By FDA

Aug. 29, 2006

By Aaron Lorenzo

EPIX's Contrast Agent Vasovist Dealt Another Setback By FDA

Aug. 29, 2006

By Aaron Lorenzo

FDA, MIT Working On Better Post-Approval Safety System

Aug. 21, 2006

By Aaron Lorenzo

FDA, MIT Working On Better Post-Approval Safety System

Aug. 21, 2006

By Aaron Lorenzo

Biotechs Should Benefit When Leadership Atop FDA Finalized

Aug. 18, 2006

By Aaron Lorenzo

Biotechs Should Benefit When Leadership Atop FDA Finalized

Aug. 18, 2006

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...